News Sentiment

ALXO sentiment intelligence

Alx Oncology Holdings news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.13 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+2.7% over one week, +34.5% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction 2.7% Price confirming higher
Trend fit Trend active 34.5% over four weeks
Fair value -52.2% Below fair value
Market Dynamics buy signal Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 35
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Market source 7
Stock Titan 7
TradingKey 6
simplywall.st 3
MarketBeat 3
The Manila Times 2
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 18
Balance sheet 1
Capital return 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Stock Titan Direct company coverage

ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations

Shelly Wong, SVP of ALX Oncology Holdings (ALXO), sold 1,404 shares of common stock at a weighted average price of $2.04 per share. This transaction was conducted to fulfill tax obligations related to the vesting of her restricted stock units. After the sale, Wong directly holds

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:39
Source
Stock Titan
Finviz Direct company coverage

ALXO - Alx Oncology Holdings Inc Options

This article provides a detailed financial overview of Alx Oncology Holdings Inc. (ALXO), including its latest stock price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as insider and institutional ownership, pr

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 09:09
Source
Finviz
Investing.com Nigeria Direct company coverage

ALX Oncology names Scott Garland chairman, adds general counsel By Investing.com

ALX Oncology Holdings Inc. has announced Scott Garland as the new Chairman of its Board of Directors and Michael Listgarten as General Counsel. Garland, with over 30 years in biopharmaceuticals, succeeds co-founder Corey Goodman, while Listgarten brings extensive legal experience

Tone
Positive 72/100
Event
Market update
Published
01 Jul 2026 09:40
Source
Investing.com Nigeria
TradingView Direct company coverage

ALX Oncology's Corey Goodman resigns as Chairman and director

Corey Goodman has resigned from his roles as Chairman and a board member of ALX Oncology, effective June 29, 2026, due to personal reasons. The company stated that his resignation was not related to any disagreements regarding operations, policies, or practices. His replacement i

Tone
Negative 41/100
Event
Market update
Published
01 Jul 2026 08:10
Source
TradingView
The Manila Times Direct company coverage

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALX Oncology Holdings Inc. announced an inducement stock option grant to its new General Counsel, Michael Listgarten, for 500,000 shares. This grant was made on June 29, 2026, as an inducement for his employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 04:56
Source
The Manila Times
Stock Titan Direct company coverage

ALX Oncology replaces its chairman and adds a new general counsel

ALX Oncology (Nasdaq: ALXO) has announced significant leadership changes, appointing Scott Garland as the new Chairman of the Board and Michael Listgarten as General Counsel, effective immediately. Garland succeeds co-founder Corey Goodman, who is stepping down after over a decad

Tone
Positive 58/100
Event
Market update
Published
30 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Leadership shifts at ALX Oncology (NASDAQ: ALXO) as Garland becomes chair

ALX Oncology Holdings Inc. (NASDAQ: ALXO) has announced a leadership transition, with co-founder and long-time Chairman Corey Goodman, Ph.D., stepping down for personal reasons effective June 29, 2026. Scott Garland, an existing independent director, has been appointed as the new

Tone
Positive 63/100
Event
Market update
Published
30 Jun 2026 20:10
Source
Stock Titan
GlobeNewswire Direct company coverage

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

ALX Oncology Holdings Inc. has announced the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel. Mr. Garland, who has served on the board since November 2022, succeeds co-founder Corey Goodman, Ph.D., who is stepping down

Tone
Positive 71/100
Event
Market update
Published
30 Jun 2026 12:09
Source
GlobeNewswire
www.marketscreener.com Direct company coverage

ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 3000E Index

ALX Oncology Holdings Inc. (NasdaqGS: ALXO) has been added to the Russell 3000E Index, as announced on June 29, 2026. This inclusion is part of several recent additions for the company to various Russell indices, including the Russell 2000, Russell 2000 Growth Benchmark, Russell

Tone
Positive 66/100
Event
Market update
Published
29 Jun 2026 20:09
Source
www.marketscreener.com
StocksToTrade Direct company coverage

ALX Oncology Holdings Inc. (ALXO) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live stock quotes and charts for ALX Oncology Holdings Inc. (ALXO) on NASDAQ, showing its current price of $2.23 and a 9.30% increase. The page also includes sections for analyst ratings (currently unavailable), earnings information, and promotional content for

Tone
Positive 76/100
Event
Earnings
Published
29 Jun 2026 18:41
Source
StocksToTrade
TradingView Direct company coverage

Price to book forward of ALX Oncology Holdings Inc. – NASDAQ:ALXO

This article provides the "Price to book forward" for ALX Oncology Holdings Inc. (NASDAQ: ALXO). It indicates that the market is closed with no current trades. The information is presented within the context of the company's financial data on TradingView.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 12:40
Source
TradingView
www.marketscreener.com Direct company coverage

ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell Microcap Index

ALX Oncology Holdings Inc. (NasdaqGS:ALXO) has been added to the Russell Microcap Index. The company is a clinical-stage biotechnology firm developing therapies for cancer, with its lead product candidate, evorpacept, currently in multiple clinical trials. This inclusion in the i

Tone
Positive 66/100
Event
Market update
Published
29 Jun 2026 05:39
Source
www.marketscreener.com
Timothy Sykes Direct company coverage

ALXO Stock Edges Higher As Jefferies Conference Spotlights Oncology Pipeline

ALX Oncology Holdings Inc. (ALXO) stock saw an 11.73% increase, driven by upcoming participation in the 2026 Jefferies Global Healthcare Conference. The company will showcase its clinical-stage oncology pipeline, particularly lead CD47 blocker evorpacept and EGFR-targeted ADC ALX

Tone
Positive 71/100
Event
Market update
Published
28 Jun 2026 14:10
Source
Timothy Sykes
StocksToTrade Direct company coverage

ALXO Rises As ALX Oncology Showcases Pipeline At Jefferies

ALX Oncology Holdings Inc. (ALXO) surged by 11.73% after showcasing its clinical-stage pipeline, including lead CD47 blocker evorpacept and EGFR-targeted ADC ALX2004, at the 2026 Jefferies Global Healthcare Conference. Despite being a clinical-stage biotech with negative profitab

Tone
Positive 74/100
Event
Market update
Published
28 Jun 2026 12:10
Source
StocksToTrade
TradingView Direct company coverage

Price to sales forward of ALX Oncology Holdings Inc. – NASDAQ:ALXO

This article provides a brief mention of the "Price to sales forward" metric for ALX Oncology Holdings Inc. (NASDAQ: ALXO). It appears to be a stub or a financial data point from TradingView, lacking detailed analysis or contextual information. The content primarily consists of n

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 10:10
Source
TradingView
Stock Titan Direct company coverage

ALX Oncology (NASDAQ: ALXO) adds up to $50M secured loan facility

ALX Oncology Holdings Inc. (NASDAQ: ALXO) has secured a new multi-tranche term loan facility of up to $50 million with HSBC Ventures USA Inc. The company immediately drew $10 million to refinance existing debt and has access to an additional $40 million, with portions contingent

Tone
Positive 59/100
Event
Balance sheet
Published
26 Jun 2026 20:10
Source
Stock Titan
TradingView Direct company coverage

ALX Oncology Holdings, Inc. Actuals & Estimates (NASDAQ:ALXO)

This article provides an overview of ALX Oncology Holdings Inc. (ALXO) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and recent earnings and revenue f

Tone
Positive 59/100
Event
Earnings
Published
26 Jun 2026 03:09
Source
TradingView
TradingView Direct company coverage

ALXO Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for ALX Oncology Holdings Inc. (ALXO) stock, including analyst ratings, EPS and revenue metrics, and historical price performance. It covers frequently asked questions regarding the stock's current price, volatility, market cap, e

Tone
Positive 60/100
Event
Earnings
Published
25 Jun 2026 17:42
Source
TradingView
TradingKey Direct company coverage

ALX Oncology Holdings Inc (ALXO) Financial Health: Profitability & Balance Sheet Analysis

ALX Oncology Holdings Inc (ALXO) has a weak financial status and low operating efficiency, ranking 367 out of 389 in the Biotechnology & Medical Research industry with a financial score of 5.40. The article notes that relevant financial data for Quality of Earnings, Operational E

Tone
Negative 39/100
Event
Earnings
Published
19 Jun 2026 03:40
Source
TradingKey
TradingKey Direct company coverage

ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of ALX Oncology Holdings Inc's (ALXO) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and reports no data available for past stock splits. The piece essentially serves as a

Tone
Neutral 50/100
Event
Capital return
Published
19 Jun 2026 03:10
Source
TradingKey
TradingKey Direct company coverage

ALX Oncology Holdings Inc (ALXO) Institutional Confidence

ALX Oncology Holdings Inc (ALXO) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 38.46%, marking a 62.05% decrease quarter-over-quarter. James Simons

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 03:10
Source
TradingKey
TradingKey Direct company coverage

ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for ALX Oncology Holdings Inc (ALXO), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It lists the current stock price, market capitalization, an

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:39
Source
TradingKey
TradingKey Direct company coverage

ALX Oncology Holdings Inc (ALXO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of ALX Oncology Holdings Inc's (ALXO) shareholder structure, listing major shareholders by proportion and category (e.g., private equity, investment advisor). It also presents institutional shareholding data over several quarters and rec

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:39
Source
TradingKey